Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01125254

Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major (AnloThal)

Sponsor: Fundação de Amparo à Pesquisa do Estado de São Paulo

Interventions Amlodipine

Updated 5 times since 2017 Last updated: Jan 2, 2015 Started: Sep 30, 2008 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01125254, this PHASE2/PHASE3 trial focuses on Thalassemia Major and remains completed. Sponsored by Fundação de Amparo à Pesquisa do Estado de São Paulo, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundação de Amparo à Pesquisa do Estado de São Paulo
University of Campinas, Brazil

Data source: University of Campinas, Brazil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Campinas, Brazil